Intero Biosystems wants drugmakers to test on mini human intestines, not animals

Intero Biosystems is offering lab-grown human intestines to pharmaceutical companies, providing an alternative to traditional animal testing methods. This initiative comes as regulatory bodies increasingly advocate for the adoption of non-animal testing protocols in drug development. The startup's primary objective is to scale up its production capabilities for these mini human intestines and further advance its organoid technology. By supplying these biomimetic models, Intero Biosystems aims to improve the efficacy and ethical considerations of drug testing, potentially leading to more accurate results that better reflect human physiological responses. This development is significant for the biotechnology sector and the pharmaceutical industry as it addresses growing concerns about animal welfare and the limitations of animal models in predicting human drug reactions, offering a more human-relevant testing platform.